Hsp90 inhibitors as senolytic drugs to extend healthy aging

Heike Fuhrmann-Stroissnigg, Laura J. Niedernhofer, Paul D. Robbins

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Aging is characterized by progressive decay of biological systems and although it is not considered a disease, it is one of the main risk factors for chronic diseases and many types of cancers. The accumulation of senescent cells in various tissues is thought to be a major factor contributing to aging and age-related diseases. Removal of senescent cells during aging by either genetic or therapeutic methods have led to an improvement of several age related disease in mice. In this preview, we highlight the significance of developing senotherapeutic approaches to specifically kill senescent cells (senolytics) or suppress the senescence-associated secretory phenotype (SASP) that drives sterile inflammation (senomorphics) associated with aging to extend healthspan and potentially lifespan. Also, we provide an overview of the senotherapeutic drugs identified to date. In particular, we discuss and expand upon the recent identification of inhibitors of the HSP90 co-chaperone as a new class of senolytics.

Original languageEnglish (US)
Pages (from-to)1048-1055
Number of pages8
JournalCell Cycle
Volume17
Issue number9
DOIs
StatePublished - May 3 2018

Fingerprint

Pharmaceutical Preparations
Cell Aging
Chronic Disease
Inflammation
Phenotype
Neoplasms
Therapeutics

Keywords

  • Aging
  • DNA damage
  • Mitochondria
  • apoptosis
  • cell senescence

Cite this

Hsp90 inhibitors as senolytic drugs to extend healthy aging. / Fuhrmann-Stroissnigg, Heike; Niedernhofer, Laura J.; Robbins, Paul D.

In: Cell Cycle, Vol. 17, No. 9, 03.05.2018, p. 1048-1055.

Research output: Contribution to journalReview article

@article{570897113be44de6a5f44ad1699b4f06,
title = "Hsp90 inhibitors as senolytic drugs to extend healthy aging",
abstract = "Aging is characterized by progressive decay of biological systems and although it is not considered a disease, it is one of the main risk factors for chronic diseases and many types of cancers. The accumulation of senescent cells in various tissues is thought to be a major factor contributing to aging and age-related diseases. Removal of senescent cells during aging by either genetic or therapeutic methods have led to an improvement of several age related disease in mice. In this preview, we highlight the significance of developing senotherapeutic approaches to specifically kill senescent cells (senolytics) or suppress the senescence-associated secretory phenotype (SASP) that drives sterile inflammation (senomorphics) associated with aging to extend healthspan and potentially lifespan. Also, we provide an overview of the senotherapeutic drugs identified to date. In particular, we discuss and expand upon the recent identification of inhibitors of the HSP90 co-chaperone as a new class of senolytics.",
keywords = "Aging, DNA damage, Mitochondria, apoptosis, cell senescence",
author = "Heike Fuhrmann-Stroissnigg and Niedernhofer, {Laura J.} and Robbins, {Paul D.}",
year = "2018",
month = "5",
day = "3",
doi = "10.1080/15384101.2018.1475828",
language = "English (US)",
volume = "17",
pages = "1048--1055",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - Hsp90 inhibitors as senolytic drugs to extend healthy aging

AU - Fuhrmann-Stroissnigg, Heike

AU - Niedernhofer, Laura J.

AU - Robbins, Paul D.

PY - 2018/5/3

Y1 - 2018/5/3

N2 - Aging is characterized by progressive decay of biological systems and although it is not considered a disease, it is one of the main risk factors for chronic diseases and many types of cancers. The accumulation of senescent cells in various tissues is thought to be a major factor contributing to aging and age-related diseases. Removal of senescent cells during aging by either genetic or therapeutic methods have led to an improvement of several age related disease in mice. In this preview, we highlight the significance of developing senotherapeutic approaches to specifically kill senescent cells (senolytics) or suppress the senescence-associated secretory phenotype (SASP) that drives sterile inflammation (senomorphics) associated with aging to extend healthspan and potentially lifespan. Also, we provide an overview of the senotherapeutic drugs identified to date. In particular, we discuss and expand upon the recent identification of inhibitors of the HSP90 co-chaperone as a new class of senolytics.

AB - Aging is characterized by progressive decay of biological systems and although it is not considered a disease, it is one of the main risk factors for chronic diseases and many types of cancers. The accumulation of senescent cells in various tissues is thought to be a major factor contributing to aging and age-related diseases. Removal of senescent cells during aging by either genetic or therapeutic methods have led to an improvement of several age related disease in mice. In this preview, we highlight the significance of developing senotherapeutic approaches to specifically kill senescent cells (senolytics) or suppress the senescence-associated secretory phenotype (SASP) that drives sterile inflammation (senomorphics) associated with aging to extend healthspan and potentially lifespan. Also, we provide an overview of the senotherapeutic drugs identified to date. In particular, we discuss and expand upon the recent identification of inhibitors of the HSP90 co-chaperone as a new class of senolytics.

KW - Aging

KW - DNA damage

KW - Mitochondria

KW - apoptosis

KW - cell senescence

UR - http://www.scopus.com/inward/record.url?scp=85052124868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052124868&partnerID=8YFLogxK

U2 - 10.1080/15384101.2018.1475828

DO - 10.1080/15384101.2018.1475828

M3 - Review article

C2 - 29886783

AN - SCOPUS:85052124868

VL - 17

SP - 1048

EP - 1055

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 9

ER -